GHRH or analogues thereof for use in treatment of hepatic disease
AssigneeThe General Hospital Corporation
InventorSteven K. Grinspoon
Life of this patent
Estimating the term…
Abstract
The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
Claims23
A method for reducing visceral fat in a subject suffering from nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH), comprising administering an effective amount of trans-3-hexenoyl-GHRH(1-44)-NH2 or a pharmaceutically acceptable salt thereof to said subject, wherein said subject has at least one of:
- (a) a hepatic fat fraction (HFF) of at least about 10%;
- (b) a reduction of hepatic fat fraction (HFF) by at least 4% (absolute reduction) following the treatment;
- and
- (c) liver fibrosis with a fibrosis score of at least 1C prior to the treatment.
Dependencies are inferred from the claim text.